Results 71 to 80 of about 7,551 (201)

Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial. [PDF]

, 2017
Background: Telbivudine has been suggested to induce hepatitis B surface antigen (HBsAg) decline to the similar degree as pegylated interferon. We aimed to investigate whether telbivudine could further decrease HBsAg titer in patients who maintain ...
���������
core   +1 more source

Impact of Metabolic Associated Steatotic Liver Disease on Antiviral Therapy Outcomes on Chronic Hepatitis B Patients Receiving Antiviral Therapy

Journal of Medical Virology, Volume 98, Issue 3, March 2026.
ABSTRACT Background and Aim Chronic hepatitis B (CHB) affects over 250 million people globally and is a major contributor to liver complications, including cirrhosis and hepatocellular carcinoma (HCC). Though antiviral therapies suppress HBV, the rising prevalence of metabolic‐associated steatotic liver disease (MASLD) poses new challenges.
Sheng‐Jie Shiue, Tung‐Han Ho, Hsin‐Yi Lin, Sheng‐Wei Cheng, Li‐Wei Wu, Tze‐Sian Chan, Chun‐Nan Chen, Chao‐Ling Cheng, Yan Kang Lee, Hsien‐Yao Yang, Han‐Shiang Shiue, Kuo‐Feng Leng, Ming‐Shun Wu   +12 more
wiley   +1 more source

Soluble immune markers in the different phases of chronic hepatitis B virus infection

Scientific Reports, 2019
Chronic hepatitis B virus (HBV) infection may follow four different consecutive phases, which are defined by virology as well as biochemical markers and differ in terms of prognosis and need for antiviral treatment. Currently, host responses reflected by
Steffen B. Wiegand, Bastian Beggel, Anika Wranke, Elmira Aliabadi, Jerzy Jaroszewicz, Cheng-Jian Xu, Yang Li, Michael P. Manns, Thomas Lengauer, Heiner Wedemeyer, Anke R. M. Kraft, Christine S. Falk, Markus Cornberg   +12 more
doaj   +1 more source

Reactivation of hepatitis B (reverse seroconversion) after melphalan/dexamethasone therapy for primary amyloidosis: a case report [PDF]

, 2015
INTRODUCTION: Hepatitis B virus (HBV) reactivation (so-called reverse seroconversion) is a rare but known complication of hematopoietic stem cell transplantation, immunosuppressive therapy, or high-dose chemotherapy plus rituximab.
Byung-Seok Choi, Choon-Hae Chung, Do-Sik Moon, JoA Kim, Sang-Gon Park, Woo-Ram Moon, Young-min Yoon   +6 more
core   +1 more source

Advances in Rapid Nucleic Acid Diagnostics for Hepatitis B and C Viruses: A Comprehensive Review

Reviews in Medical Virology, Volume 36, Issue 2, March 2026.
ABSTRACT Chronic viral hepatitis, predominantly caused by HBV and HCV infections, remains a major global health burden and a leading cause of cirrhosis, hepatocellular carcinoma (HCC), and liver‐related mortality. Achieving the World Health Organisation (WHO) target of diagnosing 90% of HBV and HCV infections by 2030 necessitates a fundamental ...
Hsin‐Ying Ho, Chia‐Yen Dai, I‐Jung Feng, Yen‐Hsu Chen, Ming‐Lung Yu, Che‐Hsin Lin, Ling‐Shan Yu   +6 more
wiley   +1 more source

Improved Safety of Nucleic Acid Amplification Technology Combined With Serological Tests for Screening Blood Donors: A Systematic Review and Meta‐Analysis

Reviews in Medical Virology, Volume 36, Issue 2, March 2026.
ABSTRACT No laboratory test performed to date provides an absolute guarantee for detecting infectious agents. Nucleic acid amplification techniques/tests (NAT) associated with serological tests can increase safety and provide greater diagnostic accuracy for patients. We investigated the added safety of NAT technology combined with serological tests for
Heloise Skiavine Madeira, Aline Ávila Brustolin, Marcos Elias da Silva Almeida, Maiara Vanusa Guedes Ribeiro, Raul Gomes Aguera, Fernando Américo Jorge, Luciana Dias Ghiraldi, Débora de Castro Moreira, Maria Valdrinez Campana Lonardoni, Dennis Armando Bertolini, Leyde Daiane de Peder, Claudinei Mesquita da Silva, Daniele Stéfanie Sara Lopes Lera‐Nonose, Áquila Carolina Fernandes Herculano Ramos‐Milaré, Jorge Juarez Vieira Teixeira   +14 more
wiley   +1 more source

Advances in immunomodulating therapy of HBV infection [PDF]

, 2000
Patients with chronic hepatitis B virus (HBV) infection have a higher risk of developing liver cirrhosis and hepatocellular carcinoma. Interferon-α, lamivudine and adefovir dipivoxil are the three approved treatment for chronic HBV infection and offers ...
Hui, CK, Lau, GKK
core  

Chronic hepatitis B - New goals, new treatment [PDF]

, 2008
published_or_final_versio
Beasley PR, Ching-Lung Lai, Lai CL, Locarnini S, Man-Fung Yuen, Yuen MF   +5 more
core   +1 more source

Genetic variants underlying precancerous conditions of hepatocellular carcinoma

International Journal of Cancer, Volume 158, Issue 3, Page 488-502, 1 February 2026.
Abstract Hepatocellular carcinoma (HCC) is the most common form of liver cancer, accounting for 80% of cases worldwide. While chronic hepatitis B and C infections remain primary risk factors, emerging evidence highlights the increasing contributions of metabolic dysfunction‐associated steatotic liver disease (MASLD) and alcohol‐associated liver disease
Jonathan Jaime G. Guerrero, Paolo C. Encarnacion, Mark Angelo S. del Rosario, Matthew Aldren S. Ora, Jiayan Zhou, Kin Israel Notarte, Wan‐Chun Li, Ching‐Wen Chang   +7 more
wiley   +1 more source

Treatment of HBeAg-Positive Hepatitis B with Peginterferon and Lamivudine: Author's replies [PDF]

, 2005
published_or_final_versio
Lau, G
core